Next Gen Sequencing Generates High Quality Data
By LabMedica International staff writers Posted on 03 Jan 2012 |
A leader in clinical diagnostics and genomic services has officially launched its Next-Gen sequencing services.
Scientists have a wide range of sequencing read options ranging from 36 base pair (bp) singleton to 150 bp paired-end reads. The system is capable of generating over 2 gigabyte (GB) data per run with a high percentage of bases over Q30.
The high data yield and superior quality allows scientists to conduct a wide variety of sequencing applications including: highly multiplexed polymerase chain reaction (PCR) amplicon sequencing, small genome sequencing and de novo sequencing, small RNA sequencing, targeted resequencing, and 16S metagenomics.
Ambry Genetics (Aliso Viejo, CA, USA) has officially launched their Next-Gen sequencing services Illumina MiSeq. Ambry Genetics has been an adapter of Illumina (San Diego, CA, USA) sequencing systems for several years and has extensive experience as a Certified Service Provider processing thousands of samples. The Illumina MiSeq uses the same established reversible-terminator sequencing by synthesis chemistry as the HiSeq2000.
"The MiSeq is a fully integrated sequencing platform enabling up to 2 GB of sequencing data using Illumina's established and reliable TruSeq technology. The quick run time and high data yield make the system ideal for amplicon and targeted resequencing projects," said Dr. Aaron Elliott, Director of Genomic Services.
Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified commercial clinical laboratory. It has become a leader in providing genetic services focused on clinical diagnostics and genomic services, particularly sequencing and array services.
Related Links:
Ambry Genetics
Illumina
Scientists have a wide range of sequencing read options ranging from 36 base pair (bp) singleton to 150 bp paired-end reads. The system is capable of generating over 2 gigabyte (GB) data per run with a high percentage of bases over Q30.
The high data yield and superior quality allows scientists to conduct a wide variety of sequencing applications including: highly multiplexed polymerase chain reaction (PCR) amplicon sequencing, small genome sequencing and de novo sequencing, small RNA sequencing, targeted resequencing, and 16S metagenomics.
Ambry Genetics (Aliso Viejo, CA, USA) has officially launched their Next-Gen sequencing services Illumina MiSeq. Ambry Genetics has been an adapter of Illumina (San Diego, CA, USA) sequencing systems for several years and has extensive experience as a Certified Service Provider processing thousands of samples. The Illumina MiSeq uses the same established reversible-terminator sequencing by synthesis chemistry as the HiSeq2000.
"The MiSeq is a fully integrated sequencing platform enabling up to 2 GB of sequencing data using Illumina's established and reliable TruSeq technology. The quick run time and high data yield make the system ideal for amplicon and targeted resequencing projects," said Dr. Aaron Elliott, Director of Genomic Services.
Ambry Genetics is a College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified commercial clinical laboratory. It has become a leader in providing genetic services focused on clinical diagnostics and genomic services, particularly sequencing and array services.
Related Links:
Ambry Genetics
Illumina
Latest Molecular Diagnostics News
- Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans
- Unique Autoantibody Signature to Help Diagnose Multiple Sclerosis Years before Symptom Onset
- Blood Test Could Detect HPV-Associated Cancers 10 Years before Clinical Diagnosis
- Low-Cost Point-Of-Care Diagnostic to Expand Access to STI Testing
- 18-Gene Urine Test for Prostate Cancer to Help Avoid Unnecessary Biopsies
- Urine-Based Test Detects Head and Neck Cancer
- Blood-Based Test Detects and Monitors Aggressive Small Cell Lung Cancer
- Blood-Based Machine Learning Assay Noninvasively Detects Ovarian Cancer
- Simple PCR Assay Accurately Differentiates Between Small Cell Lung Cancer Subtypes
- Revolutionary T-Cell Analysis Approach Enables Cancer Early Detection
- Single Genetic Test to Accelerate Diagnoses for Rare Developmental Disorders
- Upgraded Syndromic Testing Analyzer Enables Remote Test Results Access
- Respiratory and Throat Infection PCR Test Detects Multiple Pathogens with Overlapping Symptoms
- Blood Circulating Nucleic Acid Enrichment Technique Enables Non-Invasive Liver Cancer Diagnosis
- First FDA-Approved Molecular Test to Screen Blood Donors for Malaria Could Improve Patient Safety
- Fluid Biomarker Test Detects Neurodegenerative Diseases Before Symptoms Appear